Cyteir Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYT research report →
Companycyteir.com
Cyteir Therapeutics, Inc. , a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies.
- CEO
- Markus F. Renschler
- IPO
- 2021
- Employees
- 46
- HQ
- Lexington, MA, US
Price Chart
Valuation
- Market Cap
- $108.71M
- P/E
- -2.42
- P/S
- 0.00
- P/B
- 0.73
- EV/EBITDA
- 0.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -26.35%
- ROIC
- -32.37%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-43,952,000 · -5.53%
- EPS
- $-1.25 · -5.93%
- Op Income
- $-48,170,000
- FCF YoY
- -15.11%
Performance & Tape
- 52W High
- $3.19
- 52W Low
- $1.65
- 50D MA
- $3.09
- 200D MA
- $2.86
- Beta
- 0.10
- Avg Volume
- 167.62K
Get TickerSpark's AI analysis on CYT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 24 | Leonard Braden Michael | buy | 170,589 |
| Mar 18, 24 | Leonard Braden Michael | buy | 113,777 |
| Mar 15, 24 | Leonard Braden Michael | other | 0 |
| Mar 15, 24 | Leonard Braden Michael | other | 0 |
| Mar 4, 24 | Gaiero David G | other | 2,373 |
| Feb 29, 24 | Gaiero David G | other | 4,746 |
| Feb 29, 24 | Gaiero David G | other | 3,239 |
| Feb 29, 24 | Gaiero David G | other | 4,746 |
| Mar 4, 24 | Gaiero David G | other | 2,373 |
| Feb 29, 24 | Gaiero David G | other | 3,239 |
Our CYT Coverage
We haven't published any research on CYT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CYT Report →